-
Adding a P2Y12 Inhibitor Does Not Improve Outcomes in COVID-19
drugs.com
January 18, 2022
The addition of a P2Y12 inhibitor to anticoagulant therapy does not improve organ support-free days among non-critically ill patients hospitalized for COVID-19...
-
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
prnasia
January 17, 2022
Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate...
-
Eisai, Gilead Enter Exclusive Agreement for JAK Inhibitor Filgotinib in Asia
contractpharma
December 22, 2021
Eisai obtains exclusive marketing right for filgotinib in South Korea, Taiwan, China, Hong Kong, S.A.R., China and Singapore and will take over manufacturing and marketing.
-
Ascentage Pharma Presents Latest Data from Two Studies of Bcl-2-Selective Inhibitor Lisaftoclax (APG-2575), Including a China Study Demonstrating Complete Responses
prnasia
December 15, 2021
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases...
-
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
prnasia
December 01, 2021
Treadwell Therapeutics, a clinical stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) ...
-
Treadwell Therapeutics Announces A Presentation at the 2021 SITC Annual Meeting Featuring a Clinical Trial Update on CFI-402411, a First-in-Class HPK1 inhibitor
prnasia
November 15, 2021
Treadwell Therapeutics, a clinical-stage biotechnology company developing novel medicines for highly aggressive cancers, today announced a presentation for the Company's CFI-402411 program...
-
InnoCare Announces the Clearance of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 by U.S. FDA
prnasia
November 15, 2021
InnoCare Pharma (HKEX: 09969), a commercial-stage biotech company, announced today the Investigational New Drug (IND) clearance of its SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase)...
-
FDA approves label update to sodium glucose co-transporter-2 (SGLT2) inhibitors
europeanpharmaceuticalreview
March 19, 2020
Safety updates to labels of SGLT2 inhibitors will recommend temporary discontinuation of these medications before scheduled surgery, says the FDA.
-
Pulmatrix Announces Agreement with Lung Cancer Initiative
americanpharmaceuticalreview
January 06, 2020
Pulmatrix has entered into a licensing and development agreement with the Lung Cancer Initiative at Johnson & Johnson. Through the agreement, the Lung Cancer Initiative gains an option to access a portfolio of narrow spectrum kinase inhibitors intended fo
-
Dipeptidyl Peptidase-4 Inhibitors May Up Pancreatic Disease Risk
drugs
August 29, 2019
Use of dipeptidyl peptidase-4 inhibitors (DPP-4i) is associated with increased risks for pancreatitis and pancreatic cancer in patients with newly diagnosed type 2 diabetes...